{"entity":{"id":"nct07672223","kind":"trial","name":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)","aka":[],"tldr":"A phase 3 trial of SYS6010, tislelizumab, toripalimab, durvalumab and other drugs in lung cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.","summary":"A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) is a phase 3, randomised interventional study registered as NCT07672223 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 570 participants, started 2026-06-25 and due to reach its primary completion in 2029-09-30. Interventions recorded: SYS6010; Enlonstobart; Tislelizumab; Toripalimab ±+platinum-based doublet chemotherapy; Durvalumab; Pembrolizumab; Nivolumab. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Disease-Free Survival (DFS) assessed by the independent review committee (IRC). Lung eligibility wording from the registry: \"Histologically confirmed squamous or non-squamous NSCLC\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07672223","url":"https://clinicaltrials.gov/study/NCT07672223"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["sys6010","tislelizumab","toripalimab","durvalumab","pembrolizumab","nivolumab"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07672223","phase":"3","setting":"A Phase III, Randomized, Open-Label Study of SYS6010 in Combination With Anti-PD-(L)-1 Monoclonal Antibody Versus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy for Patients With Completely Resected Stage II-IIIB NSCLC Who Have No Actionable Genomic Alterations and Not Achieved a Major Pathological Response.","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","enrolled":570,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07672223/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}